Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 19, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and

Aleksandar Kuzmanov1, Souzan Salemi1, Florian A Schmid1

  • 1Laboratory for Urologic Oncology and Stem Cell Therapy, Department of Urology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland.

International Journal of Molecular Sciences
|August 12, 2023
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Heterogeneity of RCCs Assessed by mpMRI with Direct Radiological-Histopathological Correlation.

Diagnostics (Basel, Switzerland)·2026
Same author

Incidental [<sup>68</sup>Ga]Ga-DOTATATE uptake in bone metastases of breast carcinoma in a patient with a secondary carcinoid tumor.

EJNMMI research·2026
Same author

The predictive role of [<sup>177</sup>Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

Could we reduce renal toxicity of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy with furosemide?

European journal of nuclear medicine and molecular imaging·2026
Same author

Imaging occult hemorrhage in polycystic kidney disease with red blood cell scintigraphy.

European journal of nuclear medicine and molecular imaging·2026
Same author

Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET.

Radiology·2025

Dutasteride and lovastatin can increase prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Combination therapy with lower doses of these drugs enhances PSMA detection for improved imaging.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate-specific membrane antigen (PSMA)-based imaging is crucial for detecting prostate cancer.
  • Low PSMA expression can limit the effectiveness of PSMA-based diagnostic tools.
  • Pharmacological induction of PSMA may enhance detection rates.

Purpose of the Study:

  • To evaluate the effects of dutasteride (Duta) and lovastatin (Lova) on PSMA expression and cell proliferation.
  • To compare the individual impacts of Duta and Lova on PSMA upregulation.
  • To investigate if combined Duta and Lova treatments can further enhance PSMA expression.

Main Methods:

  • Testing dutasteride and lovastatin on LNCaP, C4-2, and VCaP prostate cancer cell lines.
  • Assessing changes in whole and cell surface PSMA expression.
Keywords:
androgen receptor (AR)dutasteride (Duta)dutasteride + lovastatin (Duta + Lova) treatmentlovastatin (Lova)prostate-specific membrane antigen (PSMA)

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K

Related Experiment Videos

Last Updated: Jul 19, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K
  • Comparing single-agent treatments with combination therapies at varying concentrations.

    • Main Results:

    • Treatment with dutasteride (≤1 μM) and lovastatin (≥1 μM) significantly upregulated PSMA expression.
    • Combined lower concentrations (0.5 μM Duta + 0.5 μM Lova or 0.5 μM Duta + 1 μM Lova) enhanced PSMA protein expression.
    • Combination therapy showed greater PSMA induction compared to higher single-agent concentrations across all tested cell lines.

    Conclusions:

    • Dutasteride and lovastatin effectively induce PSMA expression in prostate cancer cells.
    • Combination therapy with lower drug concentrations is a promising strategy to improve PSMA targeting.
    • This approach could enhance the sensitivity of PSMA-based imaging for prostate cancer detection.